Features | VJHemOnc

CAR-T therapy updates for the treatment of B-ALL

The introduction of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) has significantly…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

EHA 2021: updates in myeloid malignancies

VJHemOnc is excited to bring you the latest updates from research investigating the treatment and management of myeloid malignancies, as…

FDA approves daratumumab and hyaluronidase-fihj for sixth multiple myeloma indication

Last week saw the FDA approval of daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with…

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Ide-cel receives FDA approval for relapsed/refractory multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell (CAR-T) therapy, for…

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

Highlights from the EBMT-EHA CAR T-Cell Meeting & TCT 2021

Held virtually, the 3rd European EBMT-EHA CAR T-cell Meeting and the Transplantation & Cellular Therapy Meeting 2021 provided key updates…